Literature DB >> 1834157

The clinical activity of cyproterone acetate in advanced ovarian carcinoma. A London Gynaecology Oncology Group Study.

P Thompson1, P Wilson, R Osborne, M Slevin, F Wiltshaw, P Blake, P Harper, R Coleman, C Williams, J Sweetenham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1834157      PMCID： PMC1977484          DOI： 10.1038/bjc.1991.440

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  11 in total

Review 1.  Pharmacology and clinical use of antiandrogens: a short review.

Authors:  F Neumann
Journal:  Ir J Med Sci       Date:  1982-03       Impact factor: 1.568

2.  Androgen and oestrogen binding in cytosols of human ovarian tumours.

Authors:  T C Hamilton; P Davies; K Griffiths
Journal:  J Endocrinol       Date:  1981-09       Impact factor: 4.286

3.  Tamoxifen therapy of epithelial ovarian cancer.

Authors:  D R Shirey; J J Kavanagh; D M Gershenson; R S Freedman; L J Copeland; L A Jones
Journal:  Obstet Gynecol       Date:  1985-10       Impact factor: 7.661

4.  Estrogen and progestin binding in cytosols of ovarian adenocarcinomas.

Authors:  J A Holt; T A Caputo; K M Kelly; P Greenwald; S Chorost
Journal:  Obstet Gynecol       Date:  1979-01       Impact factor: 7.661

5.  Steroid receptors and progestinic therapy in ovarian endometrioid carcinoma.

Authors:  G M Rendina; C Donadio; M Giovannini
Journal:  Eur J Gynaecol Oncol       Date:  1982       Impact factor: 0.196

6.  Estrogen and progesterone receptors in ovarian neoplasms.

Authors:  L C Ford; J S Berek; L D Lagasse; N F Hacker; Y Heins; F Esmailian; R S Leuchter; R J DeLange
Journal:  Gynecol Oncol       Date:  1983-06       Impact factor: 5.482

Review 7.  Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy.

Authors:  B J Slotman; B R Rao
Journal:  Anticancer Res       Date:  1988 May-Jun       Impact factor: 2.480

8.  A phase II study of tamoxifen in ovarian cancer.

Authors:  M L Slevin; V J Harvey; R J Osborne; J H Shepherd; C J Williams; G M Mead
Journal:  Eur J Cancer Clin Oncol       Date:  1986-03

9.  Tamoxifen therapy in recurrent epithelial ovarian carcinoma.

Authors:  S A Weiner; D S Alberts; E A Surwit; J Davis; D Grosso
Journal:  Gynecol Oncol       Date:  1987-06       Impact factor: 5.482

10.  Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule.

Authors:  R J Osborne; S T Malik; M L Slevin; V J Harvey; J Spona; H Salzer; C J Williams
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640
View more
  3 in total

Review 1.  Current drug treatment guidelines for epithelial ovarian cancer.

Authors:  P C Lorigan; T Crosby; R E Coleman
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 2.  Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.

Authors:  L B Barradell; D Faulds
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

3.  Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037).

Authors:  Susana Banerjee; Holly Tovey; Rebecca Bowen; Elizabeth Folkerd; Lucy Kilburn; Jennifer McLachlan; Marcia Hall; Nina Tunariu; Ayoma Attygalle; Joao Paulo Da Silveira Nogueira Lima; Sophie Perry; Peter Chatfield; Margaret Hills; Stan Kaye; Gert Attard; Mitch Dowsett; Judith M Bliss
Journal:  Ther Adv Med Oncol       Date:  2020-12-29       Impact factor: 8.168
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.